H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Oric Pharmaceuticals today and set a price target of $23.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Robert Burns has given his Buy rating due to a combination of factors that highlight the promising potential of ORIC-944. The recent dose exploration results for ORIC-944, in combination with apalutamide or darolutamide, have shown significant efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with androgen receptor pathway inhibitors. The combination has demonstrated deep reductions in prostate-specific antigen levels, with a notable number of patients achieving significant PSA50 and PSA90 responses.
Furthermore, the combination of ORIC-944 with an ARi appears to be less toxic compared to similar treatments, enhancing its appeal as a potential best-in-class agent. The ongoing dose optimization and the expected data from the first quarter of 2026 will further inform the development of this treatment. Based on these promising results and the increased probability of approval, Burns has raised the price target for ORIC Pharmaceuticals to $23, reinforcing the Buy rating.
In another report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $15.00 price target.